JP2010527375A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010527375A5 JP2010527375A5 JP2010508596A JP2010508596A JP2010527375A5 JP 2010527375 A5 JP2010527375 A5 JP 2010527375A5 JP 2010508596 A JP2010508596 A JP 2010508596A JP 2010508596 A JP2010508596 A JP 2010508596A JP 2010527375 A5 JP2010527375 A5 JP 2010527375A5
- Authority
- JP
- Japan
- Prior art keywords
- gpr12
- long
- term memory
- memory formation
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 101700039050 GPR12 Proteins 0.000 claims 17
- 230000015572 biosynthetic process Effects 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 238000005755 formation reaction Methods 0.000 claims 15
- 230000007787 long-term memory Effects 0.000 claims 15
- 239000003795 chemical substances by application Substances 0.000 claims 13
- 230000000051 modifying Effects 0.000 claims 12
- 229940079593 drugs Drugs 0.000 claims 9
- 230000001419 dependent Effects 0.000 claims 8
- 241000124008 Mammalia Species 0.000 claims 7
- 230000036992 cognitive tasks Effects 0.000 claims 6
- 210000004727 Amygdala Anatomy 0.000 claims 4
- 238000000034 method Methods 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 230000000971 hippocampal Effects 0.000 claims 3
- 108020004459 Small Interfering RNA Proteins 0.000 claims 2
- 230000001058 adult Effects 0.000 claims 2
- 230000000692 anti-sense Effects 0.000 claims 2
- 102000004965 antibodies Human genes 0.000 claims 2
- 108090001123 antibodies Proteins 0.000 claims 2
- 239000002924 silencing RNA Substances 0.000 claims 2
- 210000001320 Hippocampus Anatomy 0.000 claims 1
- 230000003920 cognitive function Effects 0.000 claims 1
- 230000002708 enhancing Effects 0.000 claims 1
- 238000005259 measurement Methods 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 241000894007 species Species 0.000 claims 1
Claims (27)
- 有効量のGpr12 siRNA分子、生物学的に活性な有効量のGpr12アンチセンス断片および/またはGpr12タンパク質特異的な有効量の抗体の1つ以上を含む薬剤であって、哺乳動物においてGpr12活性を調節するために哺乳動物に該薬剤を投与する工程を含む方法に使用される、薬剤。
- 哺乳動物が成体哺乳動物である、請求項1記載の薬剤。
- 哺乳動物がヒトである、請求項1記載の薬剤。
- 前記投与工程により長期記憶形成の調節が生じる、請求項1記載の薬剤。
- 長期記憶形成が増強される、請求項4記載の薬剤。
- 該方法が、前記長期記憶形成の前記調節を検出する工程をさらに含む、請求項4記載の薬剤。
- 前記調節の検出工程が海馬依存性認知課題の調節の検出である、請求項6記載の薬剤。
- 前記調節の検出工程が扁桃体依存性認知課題の調節の検出である、請求項6記載の薬剤。
- 前記調節の検出工程が海馬依存性認知課題および扁桃体依存性認知課題の調節の検出である、請求項6記載の薬剤。
- Gpr12活性の調節が哺乳動物におけるGpr12タンパク質発現の調節を含む、請求項1記載の薬剤。
- 前記投与工程により認知機能の増強が生じる、請求項1記載の薬剤。
- 該方法が、特定の認知課題の成績の改善を生じるのに充分な条件下で哺乳動物を訓練する工程をさらに含む、請求項1記載の薬剤。
- 前記投与工程なしの訓練工程のみで達成される前記認知課題の成績と比較して成績増大が達成される、請求項12記載の薬剤。
- 訓練工程が複数の訓練期間を含む、請求項12記載の薬剤。
- 訓練工程が分散訓練期間を含む、請求項12記載の薬剤。
- 前記薬剤が各訓練期間の前および/または間に投与される、請求項12記載の薬剤。
- (a)Gpr12タンパク質を発現する宿主細胞に目的の薬剤を導入する工程;および(b)Gpr12機能を測定する工程を含む方法であって、前記薬剤が投与されなかった(a)の宿主細胞のGpr12機能と比較しての(b)で測定されたGpr12機能の相違によって、Gpr12機能を調節し得るものとして薬剤が同定される、方法。
- (a) Gpr12機能を調節する薬剤を非ヒト哺乳動物に投与する工程;
(b)工程(a)の非ヒト哺乳動物および前記薬剤が投与されなかった同種の対照非ヒト哺乳動物を、前記非ヒト哺乳動物において長期記憶形成が生じるのに充分な条件下で訓練する工程;
(c)工程(b)で訓練された非ヒト哺乳動物の長期記憶形成を評価する工程;ならびに
(d)工程(c)で評価された非ヒト哺乳動物の長期記憶形成を比較する工程を含む方法であって、対照非ヒト哺乳動物で評価された長期記憶形成と比較しての薬剤を投与された非ヒト哺乳動物で評価された長期記憶形成の相違によって、長期記憶形成を調節し得るものとして薬剤が同定される、方法。 - 前記非ヒト哺乳動物が成体非ヒト哺乳動物である、請求項18記載の方法。
- 前記長期記憶形成が海馬依存性長期記憶形成である、請求項18記載の方法。
- 前記長期記憶形成が扁桃体依存性長期記憶形成である、請求項18記載の方法。
- 前記長期記憶形成が海馬依存性および扁桃体依存性長期記憶形成である、請求項18記載の方法。
- Gpr12活性の調節が非ヒト哺乳動物におけるGpr12タンパク質発現の調節を含む、請求項18記載の方法。
- 訓練工程が複数の訓練期間を含む、請求項18記載の方法。
- 訓練工程が分散訓練期間を含む、請求項18記載の方法。
- 前記薬剤が各訓練期間の前および/または間に投与される、請求項18記載の方法。
- 前記薬剤が、有効量のGpr12 siRNA分子、生物学的に活性な有効量のGpr12アンチセンス断片および/またはGpr12タンパク質特異的な有効量の抗体の1つ以上を含む、請求項18記載の方法。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US93816307P | 2007-05-15 | 2007-05-15 | |
PCT/US2008/063804 WO2008144453A1 (en) | 2007-05-15 | 2008-05-15 | Methods of treating cognitive disorders by inhibition of gpr12 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010527375A JP2010527375A (ja) | 2010-08-12 |
JP2010527375A5 true JP2010527375A5 (ja) | 2011-06-23 |
Family
ID=40122145
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010508596A Pending JP2010527375A (ja) | 2007-05-15 | 2008-05-15 | Gpr12の阻害による認知障害の治療方法 |
Country Status (11)
Country | Link |
---|---|
US (2) | US7968524B2 (ja) |
EP (1) | EP2162137B1 (ja) |
JP (1) | JP2010527375A (ja) |
KR (1) | KR20100029079A (ja) |
CN (1) | CN101808647A (ja) |
AU (1) | AU2008254905A1 (ja) |
BR (1) | BRPI0811625A2 (ja) |
CA (1) | CA2684920A1 (ja) |
IL (1) | IL202091A0 (ja) |
MX (1) | MX2009012316A (ja) |
WO (1) | WO2008144453A1 (ja) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN105968022A (zh) | 2009-04-09 | 2016-09-28 | 考格尼申治疗股份有限公司 | 认知衰退的抑制剂 |
AU2010278711A1 (en) | 2009-07-31 | 2012-02-23 | Cognition Therapeutics, Inc. | Inhibitors of cognitive decline |
US20130071330A1 (en) * | 2010-02-26 | 2013-03-21 | Susan Catalano | Methods of identifying agents effective to treat cognitive decline and diseases associated therewith |
CN103458885B (zh) | 2011-02-02 | 2016-02-10 | 考格尼申治疗股份有限公司 | 由姜黄油分离的化合物及使用方法 |
ES2915833T3 (es) | 2014-01-31 | 2022-06-27 | Cognition Therapeutics Inc | Composiciones de isoindolina y métodos para tratar una enfermedad neurodegenerativa y una degeneración macular |
EP3634394A4 (en) | 2017-05-15 | 2021-04-07 | Cognition Therapeutics, Inc. | COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES |
BR102022009685A2 (pt) * | 2022-05-18 | 2023-11-28 | Fundação Oswaldo Cruz | Método para triagem de fármacos ou substâncias com potencial neuroprotetor, kit para triagem de fármacos ou substâncias, e, uso de um painel de genes |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1994018987A1 (en) * | 1993-02-19 | 1994-09-01 | Nippon Shinyaku Co., Ltd. | Drug composition containing nucleic acid copolymer |
US6291438B1 (en) * | 1993-02-24 | 2001-09-18 | Jui H. Wang | Antiviral anticancer poly-substituted phenyl derivatized oligoribonucleotides and methods for their use |
US5858988A (en) * | 1993-02-24 | 1999-01-12 | Wang; Jui H. | Poly-substituted-phenyl-oligoribo nucleotides having enhanced stability and membrane permeability and methods of use |
US5877399A (en) * | 1994-01-27 | 1999-03-02 | Johns Hopkins University | Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease |
CA2187626C (en) * | 1994-04-13 | 2009-11-03 | Michael G. Kaplitt | Aav-mediated delivery of dna to cells of the nervous system |
US5684143A (en) * | 1996-02-21 | 1997-11-04 | Lynx Therapeutics, Inc. | Oligo-2'-fluoronucleotide N3'->P5' phosphoramidates |
US6653086B1 (en) * | 1998-04-14 | 2003-11-25 | Arena Pharmaceuticals, Inc. | Endogenous constitutively activated G protein-coupled orphan receptors |
WO2001048483A2 (en) * | 1999-12-10 | 2001-07-05 | Astrazeneca Ab | Method for screening of appetite control agents |
US20040224316A1 (en) * | 2000-08-10 | 2004-11-11 | Tully Timothy P. | Augmented cognitive training |
US20060247194A1 (en) * | 2000-08-30 | 2006-11-02 | Sirna Therapeutics , Inc. | Rna interference mediated treatment of alzheimer's disease using short interfering nucleic acid (sina) |
JP4095895B2 (ja) * | 2000-12-01 | 2008-06-04 | マックス−プランク−ゲゼルシャフト ツール フォーデルング デル ヴィッセンシャフテン エー.ヴェー. | Rna干渉を媒介する短鎖rna分子 |
US6586524B2 (en) * | 2001-07-19 | 2003-07-01 | Expression Genetics, Inc. | Cellular targeting poly(ethylene glycol)-grafted polymeric gene carrier |
US20040023384A1 (en) * | 2002-07-31 | 2004-02-05 | Isis Pharmaceuticals Inc. | Antisense modulation of G protein-coupled receptor 12 expression |
US20050106731A1 (en) | 2002-08-05 | 2005-05-19 | Davidson Beverly L. | siRNA-mediated gene silencing with viral vectors |
US8729036B2 (en) * | 2002-08-07 | 2014-05-20 | University Of Massachusetts | Compositions for RNA interference and methods of use thereof |
WO2004038407A2 (en) * | 2002-10-24 | 2004-05-06 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with human g-protein coupled receptor 12 (gpr12) |
US7829694B2 (en) * | 2002-11-26 | 2010-11-09 | Medtronic, Inc. | Treatment of neurodegenerative disease through intracranial delivery of siRNA |
US20070104688A1 (en) * | 2003-02-13 | 2007-05-10 | City Of Hope | Small interfering RNA mediated transcriptional gene silencing in mammalian cells |
JP2007505617A (ja) * | 2003-09-19 | 2007-03-15 | パラダイム・セラピューティクス・リミテッド | 受容体 |
WO2005103713A2 (en) * | 2004-04-20 | 2005-11-03 | Galapagos N.V. | Methods, compositions and compound assays for inhibiting amyloid-beta protein production |
-
2008
- 2008-05-15 JP JP2010508596A patent/JP2010527375A/ja active Pending
- 2008-05-15 BR BRPI0811625-3A2A patent/BRPI0811625A2/pt not_active IP Right Cessation
- 2008-05-15 MX MX2009012316A patent/MX2009012316A/es unknown
- 2008-05-15 CA CA002684920A patent/CA2684920A1/en not_active Abandoned
- 2008-05-15 AU AU2008254905A patent/AU2008254905A1/en not_active Abandoned
- 2008-05-15 KR KR1020097024747A patent/KR20100029079A/ko not_active Application Discontinuation
- 2008-05-15 WO PCT/US2008/063804 patent/WO2008144453A1/en active Application Filing
- 2008-05-15 EP EP08755619.7A patent/EP2162137B1/en not_active Not-in-force
- 2008-05-15 CN CN200880023965A patent/CN101808647A/zh active Pending
- 2008-05-15 US US12/121,731 patent/US7968524B2/en not_active Expired - Fee Related
-
2009
- 2009-11-12 IL IL202091A patent/IL202091A0/en unknown
-
2011
- 2011-06-27 US US13/169,739 patent/US20110281936A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010527375A5 (ja) | ||
Meyer et al. | A ghrelin–growth hormone axis drives stress-induced vulnerability to enhanced fear | |
Beggiato et al. | Kynurenic acid, by targeting α7 nicotinic acetylcholine receptors, modulates extracellular GABA levels in the rat striatum in vivo | |
Han et al. | Oxytocin via its receptor affects restraint stress-induced methamphetamine CPP reinstatement in mice: Involvement of the medial prefrontal cortex and dorsal hippocampus glutamatergic system | |
Westlund et al. | Impact of central and peripheral TRPV1 and ROS levels on proinflammatory mediators and nociceptive behavior | |
Alpár et al. | Hypothalamic CNTF volume transmission shapes cortical noradrenergic excitability upon acute stress | |
JP2017538671A5 (ja) | ||
Moaddab et al. | Oxytocin receptor neurotransmission in the dorsolateral bed nucleus of the stria terminalis facilitates the acquisition of cued fear in the fear-potentiated startle paradigm in rats | |
Su et al. | Injection of corticotropin‐releasing hormone into the amygdala aggravates visceral nociception and induces noradrenaline release in rats | |
WO2010036918A3 (en) | Intracellular dna receptor | |
Raudensky et al. | Effects of chronic unpredictable stress and methamphetamine on hippocampal glutamate function | |
JP2010516678A5 (ja) | ||
Kratochwill et al. | Addition of alanyl-glutamine to dialysis fluid restores peritoneal cellular stress responses–a first-in-man trial | |
Tomar et al. | The dynamic impact of repeated stress on the hippocampal spatial map | |
Zhang et al. | Endocrine vasculatures are preferable targets of an antitumor ineffective low dose of anti-VEGF therapy | |
Fricke et al. | Glutamine uptake by System A transporters maintains neurotransmitter GABA synthesis and inhibitory synaptic transmission | |
Yoshizumi et al. | Valproate prevents dysregulation of spinal glutamate and reduces the development of hypersensitivity in rats after peripheral nerve injury | |
Carrillo-Sepulveda et al. | Phenotypic modulation of mesenteric vascular smooth muscle cells from type 2 diabetic rats is associated with decreased caveolin-1 expression | |
JP2016528914A5 (ja) | ||
Goodman et al. | Insights into the role and regulation of TCTP in skeletal muscle | |
Kang et al. | Ingestion of Bis (2-ethylhexyl) phthalate (DEHP) during adolescence causes depressive-like behaviors through hypoactive glutamatergic signaling in the medial prefrontal cortex | |
AR074450A1 (es) | Metodos y usos que implican la proteina 1 de union a hemo | |
Sadler et al. | Gabapentin alleviates chronic spontaneous pain and acute hypoxia‐related pain in a mouse model of sickle cell disease | |
Roberts et al. | Dopamine release in nucleus accumbens is under tonic inhibition by adenosine A1 receptors regulated by astrocytic ENT1 and dysregulated by ethanol | |
Bianchi et al. | Untangling the extracellular matrix of idiopathic epiretinal membrane: a path winding among structure, interactomics and translational medicine |